Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Fineline Cube Jun 24, 2026
Company Deals

AbbVie to Acquire Apogee Therapeutics for $10.9B to Expand Inflammatory Disease Pipeline

Fineline Cube Jun 24, 2026
Company Deals

BioArctic Partners with Eli Lilly on Novel Neurodegenerative Disease Therapy Using BrainTransporter Platform

Fineline Cube Jun 23, 2026
Company Deals

Haisco Pharmaceutical Secures $1.46B Global Licensing Deal with Nuvectis for BRAF and CFB Inhibitor Programs

Fineline Cube Jun 23, 2026
Company Deals Drug

MacroGenics Secures $24.5M Milestone from Sanofi Following FDA Approval Expansion for Tzield in Type 1 Diabetes

Fineline Cube Jun 23, 2026
Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Fineline Cube Jun 24, 2026
Company Drug

China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China

Fineline Cube Jun 24, 2026
Company Drug

Biokin Secures World’s First EGFR×HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma

Fineline Cube Jun 24, 2026
Company

BeiGene Launches Charitable Access Program for Brukinsa in Low-Income Countries

Fineline Cube Mar 14, 2024

BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235), the China-based biotech firm, has announced that...

Company

Innovent Biologics Denies Lab Closure, Confirms Relocation to California

Fineline Cube Mar 14, 2024

Innovent Biologics (HKG: 1801) has refuted unconfirmed reports regarding the closure of its Rockville, Maryland...

Company Deals

Novartis Acquires IFM Due for $90 Million, Expanding STING-Inhibitor Pipeline

Fineline Cube Mar 14, 2024

Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has announced the acquisition of IFM Due, a...

Company Legal / IP Policy / Regulatory

BIO Reverses Support for WuXi AppTec Amid Security Concerns, Plans Legislative Shift

Fineline Cube Mar 14, 2024

The Biotech Innovation Organization (BIO), a US-based industry lobbying group, has reversed its stance on...

Company Drug

European Commission Approves Pfizer’s Prevenar 20 for Pediatric Use

Fineline Cube Mar 14, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its 20-valent...

Company Drug

Merck Plans Broader HPV Vaccine Development, Targeting African and Asian Populations

Fineline Cube Mar 14, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has unveiled plans to develop a multi-valent human...

Company Deals

Shanghai BDgene Partners with SPH RD to Advance Gene Therapy Development

Fineline Cube Mar 14, 2024

Shanghai BDgene Technology Co., Ltd., a China-based specialist in gene therapy, has entered into a...

Company Drug

Allist Pharmaceuticals Secures NMPA Approval for Phase I Study of AST2169 Liposome in KRAS G12D Tumors

Fineline Cube Mar 14, 2024

Shanghai-based biotech Allist Pharmaceuticals Co., Ltd. (SHA: 688578) has received clearance from the National Medical...

Company Deals

BioGeometry and Sanyou Biopharmaceuticals Forge AI Partnership for Antibody Drug Discovery

Fineline Cube Mar 14, 2024

BioGeometry, an AI-driven pharmaceutical company based in Beijing, has formed a strategic partnership with Sanyou...

Company Drug

Sichuan Biokin Gains NMPA Approval for Phase I Study of BL-M05D1 in Advanced Solid Tumors

Fineline Cube Mar 14, 2024

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has received approval from the National Medical Products...

Company Drug

Genor Biopharma Secures NMPA Review for Lerociclib in Advanced Breast Cancer Indication

Fineline Cube Mar 14, 2024

Genor Biopharma Co., Ltd. (HKG: 6998) has announced that the National Medical Products Administration (NMPA)...

Company Deals

Fosun Pharma Launches RMB 5 Billion Fund to Boost Biopharmaceutical Investments in Shenzhen

Fineline Cube Mar 14, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) has unveiled plans to establish...

Policy / Regulatory

Shanghai Unveils 17 Measures to Enhance Medical Administration Business Environment

Fineline Cube Mar 14, 2024

Shanghai’s Medical Product Administration has unveiled a comprehensive set of 17 measures aimed at fostering...

Company Drug

Pfizer’s Adcetris Combo Shows Improved Survival in Relapsed/Refractory DLBCL Late-Stage Trial

Fineline Cube Mar 13, 2024

Pfizer (NYSE: PFE) has announced positive results from a late-stage clinical trial for its antibody-drug...

Company Deals

MSD Strikes Deal with Pearl Bio to Tap into Synthetic Biology for Oncology Targets

Fineline Cube Mar 13, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has entered into a strategic agreement with Pearl...

Company Deals

MSD Partners with IDEAYA Biosciences to Develop Combination Therapy for Endometrial Cancer

Fineline Cube Mar 13, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with IDEAYA Biosciences (NASDAQ:...

Company

Innovent Biologics Allegedly Closes US Research Facility, Shifts Focus to China

Fineline Cube Mar 13, 2024

Innovent Biologics (HKG: 1801), a China-based biotech firm, has reportedly closed down a research team...

Company Deals

VectorBuilder Partners with Minaris Regenerative Medicine to Enhance Gene Therapy Solutions

Fineline Cube Mar 13, 2024

VectorBuilder, a specialist in genetic engineering based in China, has entered into a strategic partnership...

Company Drug

Bio-Thera Solutions Gets Green Light for Phase Ib/II Study of ADC BAT8008 in Advanced Solid Tumors

Fineline Cube Mar 13, 2024

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received approval from the National...

Company Drug

Betta Pharmaceuticals’ Ensartinib Accepted for FDA Review for First-Line ALK+ NSCLC Treatment

Fineline Cube Mar 13, 2024

Betta Pharmaceuticals (SHE: 300558), a pharmaceutical company based in China, has announced that the market...

Posts pagination

1 … 411 412 413 … 687

Recent updates

  • China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China
  • Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital
  • Biokin Secures World’s First EGFR×HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma
  • China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted
  • Pierre Fabre Secures European Commission Approval for Braftovi Combination in BRAF-Mutant Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical System’s Silvemimab Becomes World’s First Dual-Epitope Fully Human Rabies Antibody Approved in China

Company Deals

Fusen Pharmaceutical Secures RMB 300M Strategic Investment for Henan Subsidiary Debt Restructuring and Working Capital

Company Drug

Biokin Secures World’s First EGFR×HER3 Bispecific ADC Approval with Loncomystatug Deruxtecan for Nasopharyngeal Carcinoma

Policy / Regulatory

China Launches 12th National Drug Volume-Based Procurement Batch with 65 Products, Patent Disputes Highlighted

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.